{"id":"brolucizumab-injection-beovu","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Intraocular inflammation"},{"rate":null,"effect":"Retinal detachment"}]},"_chembl":{"chemblId":"CHEMBL3707357","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brolucizumab binds to VEGF-A, a key driver of pathological neovascularization and vascular permeability in retinal diseases. By blocking VEGF-A signaling, it reduces fluid accumulation and abnormal vessel formation in conditions like wet age-related macular degeneration and diabetic macular edema. As a smaller antibody fragment compared to full monoclonal antibodies, it may offer improved retinal penetration.","oneSentence":"Brolucizumab is a single-chain antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A) to reduce abnormal blood vessel growth and leakage in the retina.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:06.163Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Wet age-related macular degeneration (AMD)"},{"name":"Diabetic macular edema (DME)"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":77,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Brolucizumab Injection [Beovu]","genericName":"Brolucizumab Injection [Beovu]","companyName":"Yeungnam University College of Medicine","companyId":"yeungnam-university-college-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brolucizumab is a single-chain antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A) to reduce abnormal blood vessel growth and leakage in the retina. Used for Wet age-related macular degeneration (AMD), Diabetic macular edema (DME).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}